effects of glp-1 receptor agonists on neurological complications of diabetes An analysis the role glucagon-like peptide-1 in cognitive and mental health disorders Glucagon-like peptide-1 medicines in neurological

Why GLP-1 Receptor Agonists Are Becoming Essential Cardiovascular Drugs Introduction Glucagon-like peptide-1 receptor agonists (GLP-1RAs)have emerged as a transformative class of medications in the management oftype 2 diabetes, demonstrating an approximate 14 percent reduction in major adverse cardiovascular events

GLP-1 receptor agonists trace their roots back to exendin-4, a peptide isolated from Gila monster venom in the early 1990san insight that eventually led to exenatide and reshaped the treatment of diabetes and metabolic disease

Compared with SGLT-2 inhibitor use, GLP-1 receptor agonist use was not associated with an increased risk of pulmonary aspiration (pooled risk ratio 0.98, 95% CI 0.73 to 1.31), although it was associated with a higher risk for discontinuation of endoscopy (1.99, 1.56 to 2.53)

These treatments can be life-changing for overall health, but their success can also bring surprising

Pfizers dose-optimization studies of once-daily formulations of danuglipron ( NCT06567327 and NCT06568731 ) met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver a competitive efficacy and tolerability profile in Phase 3 testing, based on earlier studies of twice-daily danuglipron